Developer docs
API playgroundTry for free, no card

Search company profiles

Biosplice Therapeutics

Full company profile

uuid0002sad

Namestring
Biosplice Therapeutics
Legal namestring
Biosplice Therapeutics, Inc.
Websiteurl
biosplice.com
Company typeenum
Private
Founded yearint
2008
Descriptiontext

Biosplice Therapeutics, Inc. (formerly Samumed, rebranded 2021) is a San Diego-based clinical-stage biopharmaceutical company founded in 2008 that develops small-molecule therapeutics through a proprietary alternative splicing platform targeting the Wnt signaling pathway. Its lead asset, lorecivivint (SM04690), is an injectable intra-articular CLK2/DYRK1A inhibitor that has completed Phase 3 development for knee osteoarthritis, with an NDA submitted to the FDA in January 2026. Over 1,700 subjects have been treated across the lorecivivint clinical program, demonstrating statistically significant WOMAC Pain and Function improvements versus placebo and medial joint space width improvement suggesting disease-modifying potential in an indication with no approved disease-modifying drugs and over 50 million US patients.

The company's revenue model is currently pre-commercial and combines episodic licensing upfronts and potential royalties from regional partners with prospective direct product sales upon FDA approval. Biosplice out-licensed lorecivivint development and commercialization rights to Haisco for China (September 2021, $140 million upfront) and to Samil for South Korea (April 2021), generating non-dilutive capital and validating external commercial interest. Once approved, the company plans to commercialize lorecivivint in the US via enterprise field sales targeting rheumatologists and orthopedic surgeons who administer the injection in clinical settings. A second clinical asset, cirtuvivint, is being evaluated in an investigator-initiated Phase 1 ovarian cancer trial (combination with olaparib, dosed December 2025) and in an NCI-sponsored AML/MDS trial (initiated 2024). Additional programs in neurology, diabetes, and oncology are developed by affiliate TenaRx, Inc.

Biosplice is privately held and structured as a California corporation with 51-100 employees, headquartered at 6555 Nancy Ridge Drive, Suite 300, San Diego. The company has raised approximately $778 million in cumulative disclosed equity financing across 2013, 2018, and 2021 rounds, with the $120 million April 2021 round led by aMoon Fund and Eventide. Leadership includes founder and Executive Chairman Osman Kibar, CEO Erich Horsley (private equity background at Intervale Capital and Morgan Stanley), CFO Phil Wilson, CMO Dr. Yusuf Yazici (NYU rheumatologist with 250+ publications), and Chief Legal Officer Scott Bulcao. The board includes former Foundation Medicine CEO Troy Cox and Vickers Venture Partners founder Finian Tan, and the company has been recognized among 126 healthcare unicorn startups.

Short descriptiontext

Biosplice Therapeutics is a clinical-stage biopharmaceutical company developing lorecivivint, a first-in-class injectable CLK2/DYRK1A inhibitor targeting the Wnt pathway for knee osteoarthritis, with an NDA submitted to the FDA in January 2026. The San Diego-based company serves rheumatologists and orthopedic surgeons via enterprise specialty sales and out-licenses China and Korea rights to Haisco and Samil.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
osteoarthritis therapeutics, alternative splicing platform, CLK2 DYRK1A inhibitors, Wnt pathway modulation, intra-articular injection therapy
Industry2 codes
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Osteoarthritis Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Pharmaceutical product sales
TypeOne Time License
Description

Once approved, Biosplice will generate revenue through direct sales of lorecivivint as an injectable treatment for knee osteoarthritis. The company has completed Phase 3 trials and submitted NDA to FDA.

biosplice.com
2Licensing and royalty revenue
TypeLicensing Royalties
Description

Biosplice has licensed development and commercialization rights for lorecivivint to Haisco for China (2021) and to Samil for South Korea (2021), generating upfront payments and potential royalties.

biosplice.com
3Regional partnerships
TypeLicensing Royalties
Description

The company generates revenue through regional licensing partnerships including China and Korea, with potential for additional geographic expansion.

biosplice.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Biosplice Therapeutics develops investigational disease-modifying pharmaceutical products based on its proprietary alternative splicing platform. Its lead candidate, lorecivivint (SM04690), is an injectable small-molecule CLK2/DYRK1A inhibitor that modulates the Wnt pathway to provide both symptomatic relief and structural cartilage protection in knee osteoarthritis, with an NDA submitted to the FDA in January 2026. The company also develops cirtuvivint for oncology and operates additional programs in neurology, diabetes, and oncology through affiliate TenaRx, Inc.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Statistically significant improvements in WOMAC Pain versus placebo at 6 and 12 months following single injection in OA-07 Phase 3 study
+3 more records
Product overview1 text field

Biosplice Therapeutics is a biopharmaceutical company focused on developing novel therapeutics based on its alternative splicing platform. The company's primary product is lorecivivint (SM04690), an injectable small-molecule CLK2/DYRK1A inhibitor that modulates the Wnt pathway for knee osteoarthritis treatment. Additional programs in neurology, diabetes, and oncology are being developed by its affiliate TenaRx, Inc. The company submitted an NDA to the FDA for lorecivivint in early 2026 and is also conducting clinical trials in oncology with cirtuvivint.

Product and service2 records
1Lorecivivint (SM04690)
CategoryOsteoarthritis Therapeutics
Description

Injectable small-molecule CLK2/DYRK1A inhibitor administered as a single intra-articular injection to provide disease-modifying treatment of knee osteoarthritis, offering both symptomatic pain/function relief and structural cartilage protection for adult patients who have failed conservative therapies. Targeted at rheumatologists and orthopedic surgeons.

2Cirtuvivint
CategoryOncology Therapeutics
Description

Investigational DYRK1A inhibitor drug candidate being evaluated in combination with olaparib for the treatment of BRCA/HRD platinum-resistant ovarian cancer, with the goal of overcoming resistance to PARP inhibitors.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-12-22
Description

Investigator-initiated Phase 1 clinical trial of cirtuvivint in combination with olaparib for BRCA/HRD platinum-resistant ovarian cancer being conducted at this site.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-12-01
Description

NCI-sponsored trial for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) initiated, with Biosplice's compounds being evaluated.

3Haisco
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-09-15
Description

Biosplice licensed development and commercialization rights for lorecivivint to Haisco for the People's Republic of China. Haisco paid $140 million upfront to license Biosplice's Phase 3 osteoarthritis drug for the Chinese market.

biosplice.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-04-22
Description

Biosplice licensed rights to lorecivivint to Samil for the Republic of Korea, enabling regional commercialization of the novel Phase 3 osteoarthritis drug candidate.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Biosplice sponsors the Osteoarthritis Registry of Biomarker and Imaging Trajectories (ORBIT), developed in collaboration with Brigham and Women's Hospital investigators to enhance understanding of knee osteoarthritis natural history.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Biosplice is a partner on the FNIH Biomarkers Consortium's PROGRESS OA Project, seeking to qualify imaging and biochemical biomarkers with the FDA as prognostic biomarkers of disease progression in knee osteoarthritis.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Biosplice supports STEpUP OA (Synovial fluid To define molecular Endotypes by Unbiased Proteomics in OA), an Oxford University-led partnership to characterize synovial fluid protein signatures of osteoarthritis patients.

Strategic tierCoreTypeOthers
Description

Affiliate company developing Biosplice's active programs outside of lorecivivint including neurology, diabetes and oncology programs.

Strategic tierMinorTypeOthers
Description

Biosplice is a Corporate Member of OARSI, the leading medical society for advancing understanding, early detection, treatment, and prevention of osteoarthritis through exclusive dedication to research.

10International Cartilage Regeneration & Joint Preservation Society (ICRS)
Strategic tierMinorTypeOthers
Description

Biosplice is a Corporate Member of ICRS, the main forum for international collaboration in cartilaginous tissue research and joint preservation, seeking to improve patients' quality of life and reduce degenerative joint disease impact.

biosplice.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Flexion Therapeutics (acquired by Pacira BioSciences)
TypeDirect peer
Description

Developer of Zilretta, an intra-articular extended-release corticosteroid for knee OA pain, providing the most directly comparable commercial precedent for an injectable OA therapy with rheumatologist/orthopedic surgeon channel dynamics.

TypeDirect peer
Description

Clinical-stage biotech developing EP-104IAR, an intra-articular sustained-release therapy for knee OA, sharing Biosplice's core route of administration and specialty physician targeting.

TypeDirect peer
Description

Clinical-stage company developing senolytic therapies for OA and other age-related musculoskeletal diseases, directly competing for the disease-modifying OA drug designation.

TypeDirect peer
Description

Cellular medicine company with a Phase 3 allogeneic mesenchymal precursor cell therapy for knee OA, representing an alternative modality competing for the same disease-modifying OA positioning.

TypeDirect peer
Description

Developer of TG-C, a cell and gene therapy for knee OA, advancing an intra-articular biologic approach in late-stage trials and overlapping with Biosplice's structural disease-modification thesis.

TypeBroad incumbent
Description

Public musculoskeletal specialty company with established OA offerings (hyaluronic acid injections, pain management portfolio), serving as a broader commercial incumbent in the same prescriber channels.

TypeEmerging player
Description

Clinical-stage biotech developing integrin-targeting small molecules in fibrosis and related indications, offering a comparable small-molecule biotech profile, capital base, and specialty clinical-development operating model.

8H3 Biomedicine (Eisai)
TypeEmerging player
Description

Oncology-focused RNA splicing modulator company developing small molecules targeting aberrant RNA splicing in cancer, the closest direct comparator to Biosplice's alternative splicing platform approach.

TypeBroad incumbent
Description

Co-developer (with Pfizer) of tanezumab, an anti-NGF antibody for OA pain, representing the major pharma precedent in pursuing disease-relevant OA therapies and a potential partner/acquirer for lorecivivint.

TypeBroad incumbent
Description

Acquirer of Flexion Therapeutics and operator of Zilretta in the OA space, providing a reference specialty pharma platform model for an intra-articular OA asset launch.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Biosplice Therapeutics

Osteoarthritis Therapeuticsbiosplice.com

Biosplice Therapeutics is a clinical-stage biopharmaceutical company developing lorecivivint, a first-in-class injectable CLK2/DYRK1A inhibitor targeting the Wnt pathway for knee osteoarthritis, with an NDA submitted to the FDA in January 2026. The San Diego-based company serves rheumatologists and orthopedic surgeons via enterprise specialty sales and out-licenses China and Korea rights to Haisco and Samil.

What Biosplice Therapeutics does

Biosplice Therapeutics, Inc. (formerly Samumed, rebranded 2021) is a San Diego-based clinical-stage biopharmaceutical company founded in 2008 that develops small-molecule therapeutics through a proprietary alternative splicing platform targeting the Wnt signaling pathway. Its lead asset, lorecivivint (SM04690), is an injectable intra-articular CLK2/DYRK1A inhibitor that has completed Phase 3 development for knee osteoarthritis, with an NDA submitted to the FDA in January 2026. Over 1,700 subjects have been treated across the lorecivivint clinical program, demonstrating statistically significant WOMAC Pain and Function improvements versus placebo and medial joint space width improvement suggesting disease-modifying potential in an indication with no approved disease-modifying drugs and over 50 million US patients.

The company's revenue model is currently pre-commercial and combines episodic licensing upfronts and potential royalties from regional partners with prospective direct product sales upon FDA approval. Biosplice out-licensed lorecivivint development and commercialization rights to Haisco for China (September 2021, $140 million upfront) and to Samil for South Korea (April 2021), generating non-dilutive capital and validating external commercial interest. Once approved, the company plans to commercialize lorecivivint in the US via enterprise field sales targeting rheumatologists and orthopedic surgeons who administer the injection in clinical settings. A second clinical asset, cirtuvivint, is being evaluated in an investigator-initiated Phase 1 ovarian cancer trial (combination with olaparib, dosed December 2025) and in an NCI-sponsored AML/MDS trial (initiated 2024). Additional programs in neurology, diabetes, and oncology are developed by affiliate TenaRx, Inc.

Biosplice is privately held and structured as a California corporation with 51-100 employees, headquartered at 6555 Nancy Ridge Drive, Suite 300, San Diego. The company has raised approximately $778 million in cumulative disclosed equity financing across 2013, 2018, and 2021 rounds, with the $120 million April 2021 round led by aMoon Fund and Eventide. Leadership includes founder and Executive Chairman Osman Kibar, CEO Erich Horsley (private equity background at Intervale Capital and Morgan Stanley), CFO Phil Wilson, CMO Dr. Yusuf Yazici (NYU rheumatologist with 250+ publications), and Chief Legal Officer Scott Bulcao. The board includes former Foundation Medicine CEO Troy Cox and Vickers Venture Partners founder Finian Tan, and the company has been recognized among 126 healthcare unicorn startups.

Biosplice Therapeutics firmographics

Firmographics
Name
Biosplice Therapeutics
Legal name
Biosplice Therapeutics, Inc.
Website
https://biosplice.com
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
11–50 employees
Short description
Biosplice Therapeutics is a clinical-stage biopharmaceutical company developing lorecivivint, a first-in-class injectable CLK2/DYRK1A inhibitor targeting the Wnt pathway for knee osteoarthritis, with an NDA submitted to the FDA in January 2026. The San Diego-based company serves rheumatologists and orthopedic surgeons via enterprise specialty sales and out-licenses China and Korea rights to Haisco and Samil.
Ownership category
akta.pro rank

Biosplice Therapeutics industry classification

Industry
Product category
Osteoarthritis Therapeutics
NAICS
Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Osteoarthritis therapeutics
  • Alternative splicing platform
  • CLK2 DYRK1A inhibitors
  • Wnt pathway modulation
  • Intra-articular injection therapy

Where Biosplice Therapeutics is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Biosplice Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical product sales: Once approved, Biosplice will generate revenue through direct sales of lorecivivint as an injectable treatment for knee osteoarthritis. The company has completed Phase 3 trials and submitted NDA to FDA.
  2. Licensing and royalty revenue: Biosplice has licensed development and commercialization rights for lorecivivint to Haisco for China (2021) and to Samil for South Korea (2021), generating upfront payments and potential royalties.
  3. Regional partnerships: The company generates revenue through regional licensing partnerships including China and Korea, with potential for additional geographic expansion.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Biosplice Therapeutics product offering

Product offering

Core offering

Biosplice Therapeutics develops investigational disease-modifying pharmaceutical products based on its proprietary alternative splicing platform. Its lead candidate, lorecivivint (SM04690), is an injectable small-molecule CLK2/DYRK1A inhibitor that modulates the Wnt pathway to provide both symptomatic relief and structural cartilage protection in knee osteoarthritis, with an NDA submitted to the FDA in January 2026. The company also develops cirtuvivint for oncology and operates additional programs in neurology, diabetes, and oncology through affiliate TenaRx, Inc.

Product overview

Biosplice Therapeutics is a biopharmaceutical company focused on developing novel therapeutics based on its alternative splicing platform. The company's primary product is lorecivivint (SM04690), an injectable small-molecule CLK2/DYRK1A inhibitor that modulates the Wnt pathway for knee osteoarthritis treatment. Additional programs in neurology, diabetes, and oncology are being developed by its affiliate TenaRx, Inc. The company submitted an NDA to the FDA for lorecivivint in early 2026 and is also conducting clinical trials in oncology with cirtuvivint.

Differentiator

Problem solved

Functional benefit

Products and services

  • Lorecivivint (SM04690) Injectable small-molecule CLK2/DYRK1A inhibitor administered as a single intra-articular injection to provide disease-modifying treatment of knee osteoarthritis, offering both symptomatic pain/function relief and structural cartilage protection for adult patients who have failed conservative therapies. Targeted at rheumatologists and orthopedic surgeons.
  • Cirtuvivint Investigational DYRK1A inhibitor drug candidate being evaluated in combination with olaparib for the treatment of BRCA/HRD platinum-resistant ovarian cancer, with the goal of overcoming resistance to PARP inhibitors.

Quantifiable outcome

  • Statistically significant improvements in WOMAC Pain versus placebo at 6 and 12 months following single injection in OA-07 Phase 3 study
  • +3 more outcomes

Companies that use Biosplice Therapeutics

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Biosplice Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Biosplice Therapeutics partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered minor and core.

  • University of Colorado Anschutz Cancer CenterminorStrategic or Co-development Partner · 22 December 2025Investigator-initiated Phase 1 clinical trial of cirtuvivint in combination with olaparib for BRCA/HRD platinum-resistant ovarian cancer being conducted at this site.
  • National Cancer Institute (NCI)minorStrategic or Co-development Partner · 1 December 2025NCI-sponsored trial for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) initiated, with Biosplice's compounds being evaluated.
  • HaiscocoreChannel Partner/ Reseller/ Distributor · 15 September 2021Biosplice licensed development and commercialization rights for lorecivivint to Haisco for the People's Republic of China. Haisco paid $140 million upfront to license Biosplice's Phase 3 osteoarthritis drug for the Chinese market.
  • SamilcoreChannel Partner/ Reseller/ Distributor · 22 April 2021Biosplice licensed rights to lorecivivint to Samil for the Republic of Korea, enabling regional commercialization of the novel Phase 3 osteoarthritis drug candidate.
  • Brigham and Women's Hospital at Harvard Medical SchoolminorStrategic or Co-development PartnerBiosplice sponsors the Osteoarthritis Registry of Biomarker and Imaging Trajectories (ORBIT), developed in collaboration with Brigham and Women's Hospital investigators to enhance understanding of knee osteoarthritis natural history.
  • Foundation for the National Institutes of Health (FNIH) Biomarkers ConsortiumminorStrategic or Co-development PartnerBiosplice is a partner on the FNIH Biomarkers Consortium's PROGRESS OA Project, seeking to qualify imaging and biochemical biomarkers with the FDA as prognostic biomarkers of disease progression in knee osteoarthritis.
  • Oxford UniversityminorStrategic or Co-development PartnerBiosplice supports STEpUP OA (Synovial fluid To define molecular Endotypes by Unbiased Proteomics in OA), an Oxford University-led partnership to characterize synovial fluid protein signatures of osteoarthritis patients.
  • TenaRx, Inc.coreOthersAffiliate company developing Biosplice's active programs outside of lorecivivint including neurology, diabetes and oncology programs.
  • Osteoarthritis Research Society International (OARSI)minorOthersBiosplice is a Corporate Member of OARSI, the leading medical society for advancing understanding, early detection, treatment, and prevention of osteoarthritis through exclusive dedication to research.
  • International Cartilage Regeneration & Joint Preservation Society (ICRS)minorOthersBiosplice is a Corporate Member of ICRS, the main forum for international collaboration in cartilaginous tissue research and joint preservation, seeking to improve patients' quality of life and reduce degenerative joint disease impact.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Biosplice Therapeutics competitors and assessment

Company assessment

Direct peers

  • Flexion Therapeutics (acquired by Pacira BioSciences): Developer of Zilretta, an intra-articular extended-release corticosteroid for knee OA pain, providing the most directly comparable commercial precedent for an injectable OA therapy with rheumatologist/orthopedic surgeon channel dynamics.
  • Eupraxia Pharmaceuticals: Clinical-stage biotech developing EP-104IAR, an intra-articular sustained-release therapy for knee OA, sharing Biosplice's core route of administration and specialty physician targeting.
  • UNITY Biotechnology: Clinical-stage company developing senolytic therapies for OA and other age-related musculoskeletal diseases, directly competing for the disease-modifying OA drug designation.
  • Mesoblast: Cellular medicine company with a Phase 3 allogeneic mesenchymal precursor cell therapy for knee OA, representing an alternative modality competing for the same disease-modifying OA positioning.
  • Kolon TissueGene: Developer of TG-C, a cell and gene therapy for knee OA, advancing an intra-articular biologic approach in late-stage trials and overlapping with Biosplice's structural disease-modification thesis.

Broad incumbents

  • Bioventus: Public musculoskeletal specialty company with established OA offerings (hyaluronic acid injections, pain management portfolio), serving as a broader commercial incumbent in the same prescriber channels.
  • Eli Lilly: Co-developer (with Pfizer) of tanezumab, an anti-NGF antibody for OA pain, representing the major pharma precedent in pursuing disease-relevant OA therapies and a potential partner/acquirer for lorecivivint.
  • Pacira BioSciences: Acquirer of Flexion Therapeutics and operator of Zilretta in the OA space, providing a reference specialty pharma platform model for an intra-articular OA asset launch.

Emerging players

  • Pliant Therapeutics: Clinical-stage biotech developing integrin-targeting small molecules in fibrosis and related indications, offering a comparable small-molecule biotech profile, capital base, and specialty clinical-development operating model.
  • H3 Biomedicine (Eisai): Oncology-focused RNA splicing modulator company developing small molecules targeting aberrant RNA splicing in cancer, the closest direct comparator to Biosplice's alternative splicing platform approach.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Biosplice Therapeutics social profiles

Digital presence

Biosplice Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Biosplice Therapeutics leadership team

Management profile

Number of profiles

Profiles5 records

Biosplice Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Biosplice Therapeutics funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Biosplice Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biosplice Therapeutics

What does Biosplice Therapeutics do?

Biosplice Therapeutics develops investigational disease-modifying pharmaceutical products based on its proprietary alternative splicing platform. Its lead candidate, lorecivivint (SM04690), is an injectable small-molecule CLK2/DYRK1A inhibitor that modulates the Wnt pathway to provide both symptomatic relief and structural cartilage protection in knee osteoarthritis, with an NDA submitted to the FDA in January 2026. The company also develops cirtuvivint for oncology and operates additional programs in neurology, diabetes, and oncology through affiliate TenaRx, Inc.

Is Biosplice Therapeutics a public or private company?

Biosplice Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Biosplice Therapeutics founded?

Biosplice Therapeutics was founded in 2008. It employs 11 to 50 people.

Where is Biosplice Therapeutics based?

Biosplice Therapeutics is headquartered in San Diego, United States, in the North America region.

How does Biosplice Therapeutics make money?

Three revenue lines are on record. Pharmaceutical product sales are the primary driver. The others are licensing and royalty revenue and regional partnerships.

Who are Biosplice Therapeutics's main competitors?

Direct peers on record are Flexion Therapeutics (acquired by Pacira BioSciences), Eupraxia Pharmaceuticals, UNITY Biotechnology, Mesoblast and Kolon TissueGene. Broad incumbents are Bioventus, Eli Lilly and Pacira BioSciences. Emerging players are Pliant Therapeutics and H3 Biomedicine (Eisai).

Does Biosplice Therapeutics have an API?

No public API is recorded for Biosplice Therapeutics.

What industry is Biosplice Therapeutics in?

Biosplice Therapeutics's product category is Osteoarthritis Therapeutics. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals, with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Longevity.TechnologyUK regulators accept Biosplice’s new knee osteoarthritis drug for formal reviewThe UK's MHRA accepted Biosplice's application for Lorecivivint, a knee osteoarthritis drug, for formal review. The drug, evaluated in 11 trials, showed improvements in joint structure, pain, and function, with disease modification in Phase 3 OA-07. Biosplice plans to submit to the EMA later this month and has also applied to the FDA.PR NewswireMusculoskeletal Pain Market Poised for Transformation During the Forecast Period (2026-2036) as Novel Therapies and Non-Opioid Approaches Reshape Treatment | DelveInsightThe musculoskeletal pain market is projected to grow through 2036, driven by rising prevalence of conditions like osteoarthritis and low back pain. Emerging therapies such as Rexlemestrocel-L and TLC599 are expected to reshape treatment, with the US leading the 7MM in 2025.NzzFrischkur fürs Gelenk: Wie Forscher die Arthrose heilen wollenResearchers worldwide are pursuing multiple novel approaches to cure osteoarthritis, a degenerative joint disease affecting roughly one in three Europeans. A Phase II trial of Sprifermin showed cartilage thickening in knee osteoarthritis patients but limited pain relief, while Biosplice Therapeutics has submitted FDA approval for Lorecivivint, which inhibits cartilage-degrading enzymes and showed reduced joint complaints. Additional research at institutions including Stanford University, Duke University, University of Colorado Boulder, and Columbia University, partly funded by the US government agency ARPA-H, has successfully restored near-healthy joint states in animal models using combination therapies, biomaterials, and 3D-printed implants, with human applicability still under investigation.BarchartDegenerative Disc Disease Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Mesoblast, DiscGenics, Biosplice Therapeutics, BIOPHARM GmbH, YuhanDelveInsight released a 2026 pipeline report detailing clinical trial progress and therapeutic developments for Degenerative Disc Disease, highlighting activities from companies such as DiscGenics, BioRestorative Therapies, and Angitia Biopharmaceuticals. The report notes that DiscGenics received safety board approval to proceed with its Phase III IDCT trial, while BioRestorative Therapies completed patient enrollment in its Phase II BRTX-100 study following FDA endorsement of its Phase III design. Additionally, the article mentions recent regulatory milestones including FDA approval for Companion Spine's DIAM system and CE Mark approval for ReGelTec's HYDRAFIL System.openPR.comDegenerative Disc Disease Clinical Trial Analysis 2026: Recent FDA Clearances, Ongoing Clinical Studies, and Emerging Treatment Landscape by DelveInsight | Mesoblast, DiscGenics, Biosplice TherapeuticDelveInsight published its 2026 Degenerative Disc Disease pipeline report, documenting over 15 therapeutic candidates from more than 15 companies in active clinical development, covering therapies from early preclinical stages through approved products. Key recent milestones include ReGelTec Inc.'s publication of HYDRAFIL System efficacy data (January 2026) and CE Mark approval (May 2025), Companion Spine's FDA approval of its DIAM Spinal Stabilization System (December 2025), DiscGenics' peer-reviewed study recognition (April 2025), Discure Technologies' entry into the FDA's TAP program (March 2025), and Spine BioPharma completing enrollment for its SB-01 Phase 3 trial (September 2024).openPR.comOsteoarthritis Clinical Trial Pipeline Advances as 100+ Companies Develop 110+ Novel Therapies Across All Clinical Stages, Finds DelveInsight | Biosplice Therapeutics, Regeneron PharmaceuticalsDelveInsight released its 'Osteoarthritis - Pipeline Insight, 2026' report identifying over 100 companies developing 110+ pipeline therapies across all clinical stages for osteoarthritis treatment. On March 23, 2026, Enlivex received FDA authorization to proceed with its investigational new drug application for Allocetra, enabling initiation of a global Phase 2b clinical trial for moderate-to-severe knee osteoarthritis. Biosplice Therapeutics' Lorecivivint represents the most advanced candidate in Phase III development as a potential disease-modifying osteoarthritis drug.BarchartOsteoarthritis Clinical Trial Pipeline Advances as 100+ Companies Develop 110+ Novel Therapies Across All Clinical Stages, Finds DelveInsight | Biosplice Therapeutics, Regeneron PharmaceuticalsDelveInsight released its "Osteoarthritis – Pipeline Insight, 2026" report, identifying over 100 companies developing more than 110 novel therapies for osteoarthritis across various clinical stages. The report highlights Biosplice Therapeutics' Lorecivivint as the most advanced candidate in Phase III trials and notes FDA authorization for Enlivex's Allocetra to proceed with global Phase 2b testing.Longevity.TechnologyBiosplice Therapeutics doses first patient in Phase 1 ovarian cancer trialBiosplice Therapeutics has dosed the first patient in a Phase 1 clinical trial evaluating cirtuvivint in combination with the PARP inhibitor olaparib for women with BRCA-mutated and/or HRD platinum-resistant ovarian cancer, conducted at the University of Colorado Anschutz Cancer Center and sponsored by UCHealth University of Colorado Hospital. The trial uses a dose-escalation design followed by dose-expansion to assess safety, tolerability, and recommended Phase 2 regimen in patients who have previously received PARP inhibitor therapy. Preclinical data suggest this combination may overcome or delay resistance to PARP inhibition—a common clinical challenge—by targeting both DNA repair mechanisms and adaptive survival pathways.GlobeNewswireBiosplice Therapeutics Announces First Patient Dosed in Investigator‑Initiated Phase 1 Clinical Trial of Cirtuvivint and Olaparib in BRCA/HRD Platinum‑Resistant Ovarian CancerBiosplice Therapeutics announced that the first patient has been dosed in an investigator-initiated Phase 1 clinical trial evaluating cirtuvivint in combination with olaparib in women with BRCA-mutated and/or homologous recombination-deficient (HRD) platinum-resistant ovarian cancer. The trial, sponsored by UCHealth University of Colorado Hospital and led by Dr. Bradley R. Corr, uses a dose-escalation design followed by dose-expansion to assess safety, tolerability, and determine a recommended Phase 2 dose. Preclinical studies at CU Anschutz showed that cirtuvivint, a pan-CLK/DYRK inhibitor, can disrupt WNT/TCF signaling pathways that tumor cells use to escape PARP inhibitor effects, providing rationale for this combination strategy.FailoryThe Full List of 126 Health Care Unicorn Startups (2026)The article lists 126 health care unicorn startups, including companies like Devoted Health and Biosplice Therapeutics, highlighting their valuations and contributions to the industry. It provides details about various startup valuations and investor information.